• 1
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 1536.
  • 2
    Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl 1995; 23: 20818.
  • 3
    Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Steele VE, Lubet RA, Sigman CC. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem Suppl 1995; 23: 19.
  • 4
    Supino R, Crosti M, Clerici M, Warlters A, Cleris L, Zunino F, Formelli F. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 1996; 65: 4917.
  • 5
    Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999; 91: 184756.
  • 6
    De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B, Decensi A, Veronesi U. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 2002; 86: 247.
  • 7
    De Palo G, Veronesi U, Camerini T, Formelli F, Mascotti G, Boni C, Fosser V, Del Vecchio M, Campa T, Costa A, Marubini E. Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst 1995; 87: 1467.
  • 8
    Zou CP, Kurie JM, Lotan D, Zou CC, Hong WK, Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1998; 4: 134555.
  • 9
    Sun SY, Kurie JM, Yue P, Dawson MI, Shroot B, Chandraratna RA, Hong WK, Lotan R. Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids. Clin Cancer Res 1999; 5: 4317.
  • 10
    Wu S, Zhang D, Donigan A, Dawson MI, Soprano DR, Soprano KJ. Effects of conformationally restricted synthetic retinoids on ovarian tumor cell growth. J Cell Biochem 1998; 68: 37888.
  • 11
    Zhang D, Holmes WF, Wu S, Soprano DR, Soprano KJ. Retinoids and ovarian cancer. J Cell Physiol 2000; 185: 120.
  • 12
    Sabichi AL, Hendricks DT, Bober MA, Birrer MJ. Retinoic acid receptor β expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst 1998; 90: 597605.
  • 13
    Sun SY, Li W, Yue P, Lippman SM, Hong WK, Lotan R. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 1999; 59: 24938.
  • 14
    Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 1999; 59: 148.
  • 15
    Lotan R, Clifford JL. Nuclear receptors for retinoids: mediators of retinoid effects on normal and malignant cells. Biomed Pharmacother 1991; 45: 14556.
  • 16
    Chambon P. The retinoid signaling pathway: molecular and genetic analyses. Semin Cell Biol 1994; 5: 11525.
  • 17
    DeLuca LM. Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J 1991; 5: 292433.
  • 18
    Pfahl M. Vertebrate receptors: molecular biology, dimerization and response elements. Semin Cell Biol 1994; 5: 95103.
  • 19
    Fanjul AN, Delia D, Pierotti MA, Rideout D, Yu JQ, Pfahl M, Qiu J. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996; 271: 224416.
  • 20
    Soprano DR, Chen LX, Wu S, Donigan AM, Borghaei RC, Soprano KJ. Overexpression of both RAR and RXR restores AP-1 repression in ovarian adenocarcinoma cells resistant to retinoic acid-dependent growth inhibition. Oncogene 1996; 12: 57784.
  • 21
    Wu Q, Kirschmeier P, Hockenberry T, Yang TY, Brassard DL, Wang L, McClanahan T, Black S, Rizzi G, Musco ML, Mirza A, Liu S. Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J Biol Chem 2002; 277: 3632937.
  • 22
    Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 16719.
  • 23
    Rokudai S, Fujita N, Kitahara O, Nakamura Y, Tsuruo T. Involvement of FKHR-dependent TRADD expression in chemotherapeutic drug-induced apoptosis. Mol Cell Biol 2002; 22: 8695708.
  • 24
    Hardwick JC, van Santen M, van den Brink GR, van Deventer SJ, Peppelenbosch MP. DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis 2004; 25: 12938.
  • 25
    Sokolov K, Follen M, Richards-Kortum R. Optical spectroscopy for detection of neoplasia. Curr Opin Chem Biol 2002; 6: 6518.
  • 26
    Ramanujam N. Fluorescence spectroscopy of neoplastic and non-neoplastic tissues. Neoplasia (NY). 2000; 2: 89117.
  • 27
    Wagnieres GA, Star WM, Wilson BC. In vivo fluorescence spectroscopy and imaging for oncological applications. Photochem Photobiol 1998; 68: 60332.
  • 28
    Richards-Kortum R, Sevick-Muraca E. Quantitative optical spectroscopy for tissue diagnosis. Annu Rev Phys Chem 1996; 47: 555606.
  • 29
    Lakowicz JR. Principles of fluorescence spectroscopy. New York: Plenum Press, 1983.
  • 30
    Chance B, Schoener B, Oshino R, Itshak F, Nakase Y. Oxidation–reduction ratio studies of mitochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. J Biol Chem 1979; 254: 476471.
  • 31
    Brewer M, Utzinger U, Satterfield W, Hill L, Gershenson D, Bast R, Wharton JT, Richards-Kortum R, Follen M. Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2001; 10: 88993.
  • 32
    Brewer M, Utzinger U, Li Y, Atkinson EN, Satterfield W, Auersperg N, Richards-Kortum R, Follen M, Bast R. Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. J Biomed Opt 2002; 7: 206.
  • 33
    Schantz SP, Alfano RR. Tissue autofluorescence as an intermediate endpoint in cancer chemoprevention trials. J Cell Biochem Suppl 1993; 17F: 199204.
  • 34
    Wong AS, Auersperg N. Ovarian surface epithelium: family history and early events in ovarian cancer. Reprod Biol Endocrinol 2003; 1: 70.
  • 35
    Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 1998; 16: 196977.
  • 36
    Kirkpatrick ND, Zou C, Brewer MA, Brand WR, Drezek RA, Utzinger U. Endogenous fluorescence spectroscopy of cell suspensions for chemopreventive drug monitoring. Photochem Photobiol 2005; 81: 12534.
  • 37
    Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278: 10737.
  • 38
    Boone CW, Bacus JW, Bacus JV, Steele VE, Kelloff GJ. Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials. Proc Soc Exp Biol Med 1997; 216: 15165.
  • 39
    Berchuck A, Soisson AP, Olt GJ, Soper JT, Clarke-Pearson DL, Bast RC,Jr, McCarty KS,Jr. Epidermal growth factor receptor expression in normal and malignant endometrium. Am J Obstet Gynecol 1989; 161: 124752.
  • 40
    Bast RC,Jr, Jacobs I, Berchuck A. Malignant transformation of ovarian epithelium. J Natl Cancer Inst 1992; 84: 5568.
  • 41
    Berchuck A, Boente MP, Bast RC,Jr. The use of tumor markers in the management of patients with gynecologic carcinomas. Clin Obstet Gynecol 1992; 35: 4554.
  • 42
    Bast RC,Jr, Boyer CM, Xu FJ, Wiener J, Dabel R, Woolas R, Jacobs I, Berchuck A. Molecular approaches to prevention and detection of epithelial ovarian cancer. J Cell Biochem Suppl 1995; 23: 21922.
  • 43
    Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC,Jr. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991; 164: 66974.
  • 44
    Kohler M, Janz I, Wintzer HO, Wagner E, Bauknecht T. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 1989; 9: 153747.
  • 45
    Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC,Jr. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 1991; 164: 74550.
  • 46
    Yee D, Morales FR, Hamilton TC, Von Hoff DD. Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res 1991; 51: 510712.
  • 47
    Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993; 53: 45504.
  • 48
    Di Blasio AM, Cremonesi L, Vigano P, Ferrari M, Gospodarowicz D, Vignali M, Jaffe RB. Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. Am J Obstet Gynecol 1993; 169: 151723.
  • 49
    Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 3005.
  • 50
    Davies BR, Steele IA, Edmondson RJ, Zwolinski SA, Saretzki G, von Zglinicki T, O'Hare MJ. Immortalisation of human ovarian surface epithelium with telomerase and temperature-sensitive SV40 large T antigen. Exp Cell Res 2003; 288: 390402.
  • 51
    Shin DM, Xu XC, Lippman SM, Lee JJ, Lee JS, Batsakis JG, Ro JY, Martin JW, Hittelman WN, Lotan R, Hong WK. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 1997; 3: 87580.
  • 52
    Zhang D, Vuocolo S, Masciullo V, Sava T, Giordano A, Soprano DR, Soprano KJ. Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression. Oncogene 2001; 20: 793544.
  • 53
    Pergolizzi R, Appierto V, Crosti M, Cavadini E, Cleris L, Guffanti A, Formelli F. Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. Int J Cancer 1999; 81: 82934.
  • 54
    Wu S, Zhang D, Zhang ZP, Soprano DR, Soprano KJ. Critical role of both retinoid nuclear receptors and retinoid-X-receptors in mediating growth inhibition of ovarian cancer cells by all-trans retinoic acid. Oncogene 1998; 17: 283949.
  • 55
    Wu S, Zhang ZP, Zhang D, Soprano DR, Soprano KJ. Reduction of both RAR and RXR levels is required to maximally alter sensitivity of CA-OV3 ovarian tumor cells to growth suppression by all-trans-retinoic acid. Exp Cell Res 1997; 237: 11826.
  • 56
    Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997; 89: 11918.
  • 57
    Suzuki S, Higuchi M, Proske RJ, Oridate N, Hong WK, Lotan R. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene 1999; 18: 63807.
  • 58
    Tafani M, Schneider TG, Pastorino JG, Farber JL. Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition. Am J Pathol 2000; 156: 211121.
  • 59
    Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie 2002; 84: 15366.
  • 60
    Tiwari BS, Belenghi B, Levine A. Oxidative stress increased respiration and generation of reactive oxygen species, resulting in ATP depletion, opening of mitochondrial permeability transition, and programmed cell death. Plant Physiol 2002; 128: 127181.
  • 61
    Rauh-Adelmann C, Lau KM, Sabeti N, Long JP, Mok SC, Ho SM. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Mol Carcinog 2000; 28: 23646.
  • 62
    Decensi A, Torrisi R, Bruno S, Costantini M, Curotto A, Nicolo G, Malcangi B, Baglietto L, Bruttini GP, Gatteschi B, Rondanina G, Varaldo M, et al. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomarkers Prev 2000; 9: 10718.
  • 63
    Brewer M, Wharton JT, Wang J, McWatters A, Auersperg N, Gershenson D, Bast R, Zou C. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. Gynecol Oncol 2005; 98: 18292.
  • 64
    Follen M, Atkinson EN, Schottenfeld D, Malpica A, West L, Lippman S, Zou C, Hittelman WN, Lotan R, Hong WK. A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin Cancer Res 2001; 7: 335665.
  • 65
    Broaddus RR, Xie S, Hsu CJ, Wang J, Zhang S, Zou C. The chemopreventive agents 4-HPR and DFMO inhibit growth and induce apoptosis in uterine leiomyomas. Am J Obstet Gynecol 2004; 190: 68692.
  • 66
    Zou C, Vlastos AT, Yang L, Wang J, Brewer M, Follen M. Effect of 4-hydroxyphenylretinamide on human cervical epithelial and cancer cell lines. J Soc Gynecol Investig 2003; 10: 418.
  • 67
    Zou C, Liebert M, Grossman HB, Lotan R. Identification of effective retinoids for inhibiting growth and inducing apoptosis in bladder cancer cells. J Urol 2001; 165: 98692.